Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals is a clinical stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough. The company's business model is highly capital efficient and strives to deliver maximum shareholder value. Algernon's unique approach to drug discovery is based on the concept of drug repurposing.


Recent & Breaking News (CSE:AGN)

Algernon Pharmaceuticals (CSE:AGN) screens first subject in Phase 1 DMT Human Stroke Study

Jon Brown 11 days ago

Algernon Pharmaceuticals Screens First Subject in Phase 1 DMT Human Stroke Study

GlobeNewswire 11 days ago

Algernon Pharmaceuticals: Advancing DMT into a Phase 1 Clinical Trial, CEO Clips Video

Newsfile November 8, 2022

Algernon Pharmaceuticals (CSE:AGN) enters into a clinical trial with Yale University for a DMT Phase 2 Depression study

Jon Brown October 24, 2022

Algernon Pharmaceuticals Enters into a Clinical Trial Agreement with Yale University for a DMT Phase 2 Depression Study

GlobeNewswire October 24, 2022

Algernon Pharmaceuticals Announces Dr. Rick Strassman author of "DMT: The Spirit Molecule" to Join CEO Christopher J. Moreau for Keynote Science Address at Wonderland Conference

GlobeNewswire October 14, 2022

Algernon Pharmaceuticals (CSE:AGN) receives C$450K cash refund from Australian research program

Azuka Onwuka September 21, 2022

Algernon Pharmaceuticals Announces Receipt of CDN $450K Cash Refund from Australian Research Program

GlobeNewswire September 21, 2022

Algernon Pharmaceuticals Files for Orphan Designation with the U.S. FDA for Ifenprodil as a Treatment of IPF

GlobeNewswire September 19, 2022

Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT Human Stroke Study

GlobeNewswire September 12, 2022

Algernon (CSE:AGN) secures lead sponsorship of 2022 Wonderland Psychedelic Conference in Miami

Shoran Devi September 8, 2022

Algernon Pharmaceuticals Secures Lead Sponsorship of 2022 Wonderland Psychedelic Conference in Miami

GlobeNewswire September 8, 2022

Microdose Announces Algernon Pharmaceuticals as Wonderland's Headline Sponsor

Newsfile September 8, 2022

Algernon Pharmaceuticals (CSE:AGN) reports positive results of its Phase 2 Ifenprodil study

John Ballem  September 1, 2022

Algernon Pharmaceuticals Reports Positive Results from Full Data Set of its Phase 2 Study of Ifenprodil for IPF and Chronic Cough

GlobeNewswire September 1, 2022

Algernon Pharmaceuticals (CSE:AGN) shareholder AlphaNorth Asset Management increases ownership position

Brieanna McCutcheon  August 23, 2022

Algernon Pharmaceuticals Inc. (CSE:AGN) closes private placement

Azuka Onwuka August 23, 2022

Algernon Pharmaceuticals' Largest Shareholder AlphaNorth Asset Management Increases Ownership Position

GlobeNewswire August 23, 2022

Algernon Pharmaceuticals Announces Closing of Private Placement

GlobeNewswire August 23, 2022

Algernon Pharmaceuticals (CSE:AGN) announces $1.4M private placement

John Ballem  August 18, 2022